70-07-5

Basic information

• Product Name: Mephenoxalone
• Synonyms: mephenoxalone;5-[(2-Methoxyphenoxy)methyl]-2-oxazolidinone;5-[(2-methoxyphenoxy)methyl]-1,3-oxazolidin-2-one;5-[(2-methoxyphenoxy)methyl]oxazolidin-2-one;5-(o-MethoxyphenoxyMethyl)-2-oxazolidinone;Dorsiflex;Methoxydone;Metoxadone
• CAS NO: 70-07-5
• Molecular Formula: C₁₁H₁₃NO₄
• Molecular Weight: 223.22
• EINECS: 200-723-3
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 70-07-5.mol

Chemical Properties

• Melting Point: 143-145°
• Boiling Point: 364.51°C (rough estimate)
• Flash Point: 219.9°C
• Appearance: /
• Density: 1.2446 (rough estimate)
• Vapor Pressure: 6.09E-08mmHg at 25°C
• Refractive Index: 1.4960 (estimate)
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 12.24±0.40(Predicted)
• CAS DataBase Reference: Mephenoxalone(CAS DataBase Reference)
• NIST Chemistry Reference: Mephenoxalone(70-07-5)
• EPA Substance Registry System: Mephenoxalone(70-07-5)

Safety Data

• Hazardous Substances Data: 70-07-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Mephenoxalone is used as a muscle relaxant for the treatment of muscle spasms and pain. It helps to relieve muscle stiffness and discomfort by reducing the involuntary contractions of the muscles.
Mephenoxalone is also used as a mild tranquilizer to alleviate anxiety and tension. It works by depressing the central nervous system, providing a calming effect and promoting relaxation.
In addition to its primary uses, Mephenoxalone may also be used in combination with other medications for specific therapeutic purposes, such as in the treatment of certain types of headaches or as an adjunct therapy for pain management. However, it is important to note that the use of Mephenoxalone should always be under the guidance and supervision of a healthcare professional to ensure its safe and effective use.

Originator

Trepidone,Lederle, ,1961

Manufacturing Process

A mixture of 24.1 g (0.10 mol) of 3-o-methoxyphenoxy-2-hydroxy-1-propyl carbamate and 6.0 g (0.10 mol) of urea was heated rapidly to the temperature range of 180°C to 200°C, and maintained there for five hours. The reaction melt was poured into 50% ethyl alcohol, from which the product crystallized as a white solid. The crude yield was 18.3 g (82%); melting point 131.5% to 137°C. Crystallization from water and 95% alcohol gave 9.0 g (40.3 %) of pure 5-o-methoxyphenoxymethyl-2-oxazolidone; melting point 141°C to 143°C. This melting point was not depressed when the material was mixed with an authentic sample. In additional runs acetone was used instead of ethyl alcohol with equivalent results. It was found that when the heating time was reduced to three hours and a reaction temperature of 190°C to 200°C was maintained, equivalent yields (40 to 50%) were obtained, but that the yields were appreciably lowered when the heating time was further reduced to two hours. It was also found that when the temperature was lowered to the range of 170°C to 180°C the yield was significantly lowered.When the material was isolated by extraction with chloroform and distillation, the yield of pure material was 58.5%.

Therapeutic Function

Tranquilizer

InChI:InChI=1/C11H13NO4/c1-14-9-4-2-3-5-10(9)15-7-8-6-12-11(13)16-8/h2-5,8H,6-7H2,1H3,(H,12,13)

Upstream product

• 93-14-1 guaifenesin 
• 57-13-6 urea 
• 60420-27-1 N-propionyloxazolidin-2-one 
• 870-63-3 prenyl bromide 
• 590-28-3 potassium cyanate 
• 25772-81-0 1-chloro-3-(2-methoxyphenoxy)-2-propyl alcohol 
• 124-38-9 carbon dioxide 
• 943962-56-9 1-azido-3-(2-methoxyphenoxy)propan-2-ol 
• 176491-82-0 3-Benzyloxy-1-butoxycarbonylamino-4-nitrobenzene 
• 2510-33-0 N-benzyl-2-oxazolidinone 
• 153756-96-8 4-acetamidophenyl N-<3-(2-methoxyphenoxy)-2-hydroxypropyl>carbamate 

Downstream Products

• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 
• 181997-12-6 (S)-[3-[3-Fluoro-4-(1H-imidazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methylazide 
• 181997-16-0 (S)-[3-[3-Fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methylazide 
• 104-21-2 p-methoxybenzyl acetate 
• 202344-79-4 (S)-3-((2'R)-allyl-1'-oxononanoyl)-4-phenyl ethyl-2-oxazolidinone 
• 366789-02-8 Rivaroxaban 
• 159707-16-1 (4S)-benzyl-3-[2'-(4-fluorophenyl)acetyl]-2-oxazolidinone 
• 313653-10-0 (3S,5R)-5-methyl-3-((4R,5S)-4-methyl-2-oxo-5-phenyloxazolidine-3-carbonyl)octanoic acid tert-butyl ester 
• 313653-09-7 (4R,5S)-4-methyl-3-((R)-4-methylheptanoyl)-5-phenyloxazolidin-2-one 
• 313653-38-2 (3S,5R)-5-Methyl-3-((4R,5S)-4-methyl-2-oxo-5-phenyl-oxazolidine-3-carbonyl)-nonanoic Acid Tert-butyl Ester 
• 313653-37-1 (4R,5S)-4-methyl-3-((R)-4-methyl-octanoyl)-5-phenyl-oxazolidin-2-one 

Relevant articles and documents

A facile Ph3P/CO2 mediated, one-pot synthesis of 2-oxazolidinones from 1, 2-azido alcohols via phosphazene and isocyanate intermediates

A facile, efficient and convenient method has been developed for the one-pot synthesis of 2-oxazolidinones from the corresponding 1, 2-azido alcohols via phosphazene and isocyanate intermediates in presence of Ph 3P/CO2 in toluene.

DMAP-catalyzed synthesis of 2-oxazolidinones from corresponding halohydrins using KOCN/DMF

We report facile and simple synthesis of a variety of 2-oxazolidinones from the corresponding halohydrins by reaction with KOCN in DMF catalyzed by DMAP. DMAP and temperature play key roles in enriching the yield of 2-oxazolidinones. A few examples in this Letter are applicable to pharmaceutically important processes.

THERAPEUTIC COMPOSITIONS CONTAINING GLUTATHIONE ANALOGS

Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.

Antitumoral compounds

New spisulosine derivatives of use in treating tumors are of the formula (I) wherein: each X is the same or different, and represents H, OH, OR′, SH, SR′, SOR′, SO2R′, NO2, NH2, NHR′, N(R′)2, CN, halogen, C(=O)H, C(=O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups X may together form =O; Y is NR1, OR1, PR1, SR1, or halogen, wherein the number of substituents R1 is selected to suit the valency and each R1 is independently selected of H, OH, C(=O)R′, P(=O)R′R″, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, and wherein the dotted line indicates an optional double bond; each Z is the same different, and represents H, OH, OR′, SH, SR′, SOR′, SO2R′, NO2, NH2, NHR′, N(R′)2, NHC(O)R′, CN, halogen, C(=O)H, C(=O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups Z may together form =O; z is 0 to 25; y is to 0 to 20; R2 is H, C(=O)R′, P(=O)R′R″, S(=O)R′R″, S(=O)2R′, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 Alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl; R3 is H, C(=O)R′, P(=O)R′R″, S(=O)R′R″, S(=O)2R′, substituted or unsubstituted C1-C18 alklyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl; each of the R′, R″ groups is independently selected from the group consisting of H, OH, NO2, NH2, SH, CN, halogen, =O, C(=O)H, C(=O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C1-C18 alkoxy, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynl, substituted or unsubstituted aryl; there may be one or more unsaturations in the hydrocarbon backbone defined by the chain (II) and salts thereof; with the exception of a C16-C24 2-amino-3-hydroxyalkane or a C16-C24 2-amino-3-hydroxyalkene.

DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention further provides a method of treating a subject suffering from urinary incontinence which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's urinary incontinence.

NOVEL FLORFENICOL-TYPE ANTIBIOTICS

The present invention relates to novel florfenicol compounds having the chemical structure: wherein the compounds are useful for the treatment and/or prevention of bacterial infections in a broad range of patients such as, without limitation, birds, fish, shellfish and mammals

RNA binding compounds and uses thereof

A method for determining whether a test compound binds to a large RNA target, comprising the steps of: (a) contacting the test compound with a pair of indicator molecules comprising (i) a fluorescent oxazolidinone or aminoglycoside reporter molecule and (ii) the large RNA target; and (b) measuring the fluorescence of reporter molecule in the presence of the test compound and comparing this value to the fluorescence of the reporter in the absence of the test compound. It has been found that large RNA molecule are advantageous in this type of binding assay.

Hydroxypropyl amides for the treatment of Alzheimer's disease

The present invention relates to compounds of formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.

Pyridoquinoxaline antivirals

The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof wherein R1, R2 and R3 are as defined in the specification. The compounds are useful for the treatment of viral infections.

Novel lactam inhibitors of hepatitis C virus NS3 protease

The present invention relates to lactams of Formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.